Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Sarcoma 69Osteosarcoma 29Sarcoma, Ewing 20Rhabdomyosarcoma 17Ovarian Neoplasms 17Melanoma 17Neuroblastoma 15Gastrointestinal Stromal Tumors 15Colorectal Neoplasms 12Bone Neoplasms 12Wilms Tumor 11Sarcoma, Kaposi 11Rhabdoid Tumor 11Neoplasms 11Lymphoma, Non-Hodgkin 10Hepatoblastoma 10Glioma 10Breast Neoplasms 10Stomach Neoplasms 9Medulloblastoma 9Liposarcoma 9Ependymoma 9Neurofibrosarcoma 8Neuroectodermal Tumors, Primitive, Peripheral 8Neoplasm Metastasis 8Head and Neck Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Hepatocellular 8Prostatic Neoplasms 7Pancreatic Neoplasms 7

Interventions

fludarabine 1aldesleukin 1Nivolumab 1Ipilimumab 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Giant Cell Tumor of Bone × Sarcoma × 30 days × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡